Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial
Authors:
- 20 November 2025
- journal article
- clinical trial-protocol
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 160, 108150
Abstract
No abstract availableKeywords
Funding Information
- Innovent Biologics
This publication has 40 references indexed in Scilit:
- The effect of GLP-1RAs on mental health and psychotropics-induced metabolic disorders: A systematic reviewPsychoneuroendocrinology, 2025
- Rapid increasing burden of diabetes and cardiovascular disease caused by high body mass index in 1.25 million Chinese adults, 2005–2018Med, 2023
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trialThe Lancet, 2023
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trialeClinicalMedicine, 2022
- Why does obesity cause diabetes?Cell Metabolism, 2022
- Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversationThe Lancet, 2022
- IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b studyeClinicalMedicine, 2021
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialThe Lancet, 2021
- Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th editionDiabetes Research and Clinical Practice, 2019
- ObesityJournal of the American Association of Nurse Practitioners, 2017